The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats.

about

The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats.

Item

http://www.wikidata.org/entity/Q55340936

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

The soluble guanylate cyclase ...... al pressure in cirrhotic rats.

@en

The soluble guanylate cyclase ...... al pressure in cirrhotic rats.

@nl

type

Item

label

The soluble guanylate cyclase ...... al pressure in cirrhotic rats.

@en

The soluble guanylate cyclase ...... al pressure in cirrhotic rats.

@nl

prefLabel

The soluble guanylate cyclase ...... al pressure in cirrhotic rats.

@en

The soluble guanylate cyclase ...... al pressure in cirrhotic rats.

@nl

P1476

The soluble guanylate cyclase ...... tal pressure in cirrhotic rats

@en

P2093

Alexander Pfeifer

http://www.w3.org/2001/XMLSchema#string

Bruno Karl Podesser

http://www.w3.org/2001/XMLSchema#string

David Bauer

http://www.w3.org/2001/XMLSchema#string

Diana Bonderman

http://www.w3.org/2001/XMLSchema#string

Florian Riedl

http://www.w3.org/2001/XMLSchema#string

Georg Oberhuber

http://www.w3.org/2001/XMLSchema#string

Hubert Hayden

http://www.w3.org/2001/XMLSchema#string

Jonel Trebicka

http://www.w3.org/2001/XMLSchema#string

Judith Stift

http://www.w3.org/2001/XMLSchema#string

Ksenia Brusilovskaya

http://www.w3.org/2001/XMLSchema#string

P2860

NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential

Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle

Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase)

Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence.

Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.

Riociguat for the treatment of pulmonary arterial hypertension.

The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough.

Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding.

Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension.

Fibrosis in autoimmune and cholestatic liver disease

P304

9372

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-018-27656-Y

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29921982

http://www.w3.org/2001/XMLSchema#string

P932

6008436

http://www.w3.org/2001/XMLSchema#string